← All trials
NCT04171531
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- May 31, 2023
- Completion date
- May 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pelvic Floor Disorders NetworkLead sponsor
- National Institutes of Health (NIH)Collaborator
- Duke UniversityCollaborator
- University of California, San DiegoCollaborator
- University of PennsylvaniaCollaborator
- University of PennsylvaniaOverall official - principal investigator
- University of Alabama, BirminghamCollaborator
- University of PittsburghCollaborator
- The University of Texas, DallasCollaborator
- Kaiser PermanenteCollaborator
- Brown UniversityCollaborator
- RTI InternationalCollaborator
- RTI InternationalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.